Literature DB >> 9246574

Neutrophil chemotactic activity and C5a following systemic activation of complement in rats.

E Schmid1, R L Warner, L D Crouch, H P Friedl, G O Till, T E Hugli, P A Ward.   

Abstract

Using ELISA analysis, rat C5a was stimulated in serum from rats undergoing systemic activation of complement after intravenous infusion of purified cobra venom factor (CVF). Biological (neutrophil chemotactic) activity was also assessed. Serum levels of C5a were directly proportional to the amount of CVF infused. C5a and neutrophil chemotactic activity, peaked by 5 min, then plateaued. In vitro addition of anti-C5a to serum samples of CVF-infused rats totally abolished chemotactic activity, indicating that all biological activity could be ascribed to C5a. Blood neutrophils obtained from CVF-infused animals showed a significant upregulation of CD11b, the increase being reduced (38%) in animals pretreated with anti-C5a. These findings indicate that infusion of CVF into rats produces generation of C5a, all chemotactic activity in serum being related to C5a. The in vivo generation of C5a is, at least inpart, responsible for upregulation of CD11b on blood neutrophils.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246574     DOI: 10.1023/a:1027302017117

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  16 in total

1.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

Review 2.  The role of complement in the induction and regulation of immune responses.

Authors:  T G Egwang; A D Befus
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

3.  Cobra venom factor: improved method for purification and biochemical characterization.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  J Immunol Methods       Date:  1984-10-12       Impact factor: 2.303

4.  Immunological, structural and functional relationships between an anti-complementary protein from Crotalus atrox venom, cobra venom factor and human C3.

Authors:  J O Minta; D Man
Journal:  Immunology       Date:  1980-04       Impact factor: 7.397

5.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

6.  Requirement and role of C5a in acute lung inflammatory injury in rats.

Authors:  M S Mulligan; E Schmid; B Beck-Schimmer; G O Till; H P Friedl; R B Brauer; T E Hugli; M Miyasaka; R L Warner; K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140).

Authors:  M S Mulligan; M J Polley; R J Bayer; M F Nunn; J C Paulson; P A Ward
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury.

Authors:  P A Ward; G O Till; R Kunkel; C Beauchamp
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

9.  Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency.

Authors:  L Cui; D F Carney; T E Hugli
Journal:  Protein Sci       Date:  1994-08       Impact factor: 6.725

10.  Systemic complement activation, lung injury, and products of lipid peroxidation.

Authors:  P A Ward; G O Till; J R Hatherill; T M Annesley; R G Kunkel
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more
  7 in total

1.  Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.

Authors:  R F Guo; M Huber-Lang; X Wang; V Sarma; V A Padgaonkar; R A Craig; N C Riedemann; S D McClintock; T Hlaing; M M Shi; P A Ward
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Differing patterns of P-selectin expression in lung injury.

Authors:  N M Bless; S J Tojo; H Kawarai; Y Natsume; A B Lentsch; V A Padgaonkar; B J Czermak; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

3.  Novel chemokine responsiveness and mobilization of neutrophils during sepsis.

Authors:  Cecilia L Speyer; Hongwei Gao; Nicholas J Rancilio; Thomas A Neff; Gary B Huffnagle; J Vidya Sarma; Peter A Ward
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Enhancement of COPD biological networks using a web-based collaboration interface.

Authors:  Stephanie Boue; Brett Fields; Julia Hoeng; Jennifer Park; Manuel C Peitsch; Walter K Schlage; Marja Talikka; Ilona Binenbaum; Vladimir Bondarenko; Oleg V Bulgakov; Vera Cherkasova; Norberto Diaz-Diaz; Larisa Fedorova; Svetlana Guryanova; Julia Guzova; Galina Igorevna Koroleva; Elena Kozhemyakina; Rahul Kumar; Noa Lavid; Qingxian Lu; Swapna Menon; Yael Ouliel; Samantha C Peterson; Alexander Prokhorov; Edward Sanders; Sarah Schrier; Golan Schwaitzer Neta; Irina Shvydchenko; Aravind Tallam; Gema Villa-Fombuena; John Wu; Ilya Yudkevich; Mariya Zelikman
Journal:  F1000Res       Date:  2015-01-29

5.  Regulatory effects of iNOS on acute lung inflammatory responses in mice.

Authors:  Cecilia L Speyer; Thomas A Neff; Roscoe L Warner; Ren-Feng Guo; J Vidya Sarma; Niels C Riedemann; Megan E Murphy; Hedwig S Murphy; Peter A Ward
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

6.  Houttuyniacordata Thunb. polysaccharides ameliorates lipopolysaccharide-induced acute lung injury in mice.

Authors:  Yan-Yan Xu; Yun-Yi Zhang; Ying-Ye Ou; Xiao-Xiao Lu; Ling-Yu Pan; Hong Li; Yan Lu; Dao-Feng Chen
Journal:  J Ethnopharmacol       Date:  2015-07-17       Impact factor: 4.360

7.  Cobra Venom Factor Boosts Arteriogenesis in Mice.

Authors:  Philipp Götz; Sharon O Azubuike-Osu; Anna Braumandl; Christoph Arnholdt; Matthias Kübler; Lisa Richter; Manuel Lasch; Lisa Bobrowski; Klaus T Preissner; Elisabeth Deindl
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.